Status:
COMPLETED
Glycine vs Placebo for the Schizophrenia Prodrome
Lead Sponsor:
Yale University
Collaborating Sponsors:
Glytech, Inc
National Alliance for Research on Schizophrenia and Depression
Conditions:
Schizophrenia Prodrome
Eligibility:
All Genders
13-35 years
Phase:
PHASE2
PHASE3
Brief Summary
Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater...
Detailed Description
A pilot clinical trial comparing glycine to placebo in patients with the schizophrenia prodrome.
Eligibility Criteria
Inclusion
- meet SIPS criteria for schizophrenia prodrome
Exclusion
- history of psychosis
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00291226
Start Date
March 1 2006
End Date
July 1 2009
Last Update
April 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PRIME Clinic
New Haven, Connecticut, United States, 06519